Tegoprubart

Eledon is a Nasdaq-listed biotech in Irvine, California. Its main programme is tegoprubart to prevent rejection after kidney transplants. ALS is listed in its pipeline as a completed Phase 2 biomarker study; a June 2026 company presentation said Eledon is seeking non-equity financing to take it to Phase 3.

CD40 ligand is a protein on immune cells that switches on inflammatory responses. In ALS, inflammation in the nervous system is thought to add to motor neuron damage. Tegoprubart blocks CD40 ligand with the aim of turning down that inflammation.

The 54-person Phase 2a trial finished in 2022 and was published in 2024. In its August 2026 quarterly report, Eledon said it cannot continue ALS development without additional funding dedicated to ALS. No Phase 3 trial has been scheduled.

This was a small, open-label trial without a placebo group, testing four dose levels over 12 weeks. It was safe and well tolerated, and 18 pro-inflammatory markers in the blood went down. The ALS functional score (ALSFRS-R) fell by 0.99 points a month across all 54 people, which the authors describe as similar to the natural course of ALS, and there was no dose-related pattern. The company's comparison with past trial patients only looked favourable after leaving some participants out. The study was not designed to show an effect on symptoms or survival.

This is the most favourable result reported. See all key studies for the full picture.

The Phase 2a trial enrolled 54 adults with ALS at sites in the US and Canada. Infusions were given every two weeks, six times in total.

Eledon has said since early 2025 that it wants to run a fully powered ALS Phase 3 trial but only with outside funding such as grants or partners. It has not announced any such funding or a start date.

The only ALS trial is finished, and no expanded access programme for ALS has been announced. Current tegoprubart trials are in kidney transplantation.

• Phase 2a open-label study in ALS (NCT04322149) completed · USA, Canada